Sign In
Buy RVVTF
$0.0216
-0.0039 (-15.29%)
At Close: Jun 03, 2026
Company to advance additional preclinical studies and pursue government partnership opportunities for bucillamine as a potential franchise asset for infectious diseases, nerve-agent exposure, future p
Patent momentum expands Revive's bucillamine franchise across medical countermeasures, infectious diseases and additional high-value strategic applications TORONTO, ON / ACCESS Newswire / March 11, 20
Revive Therapeutics Provides Update of Key Nerve Agent Countermeasure Study
07:30am, Monday, 15'th Dec 2025
TORONTO, Dec. 15, 2025 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT: 31R), a specialty life sciences company focused on the res
Revive Therapeutics Provides Update of Key Nerve Agent Countermeasure Study
12:07pm, Friday, 21'st Nov 2025
TORONTO, Nov. 21, 2025 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT: 31R), a specialty life sciences company focused on the res
Revive Therapeutics Announces Closing of Second Tranche of Private Placement
05:00pm, Friday, 19'th Sep 2025
TORONTO, Sept. 19, 2025 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT: 31R), a specialty life sciences company dedicated to dev
Revive Therapeutics Announces Extension of Proposed Private Placement
07:50pm, Friday, 05'th Sep 2025
TORONTO, Sept. 05, 2025 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd.
Revive Therapeutics Announces Closing of First Tranche of Private Placement and Debt Settlement
07:28pm, Monday, 11'th Aug 2025
TORONTO, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT: 31R), a specialty life sciences company dedicated to devel
Revive Therapeutics Announces Proposed Private Placement and Debt Settlement
08:21pm, Wednesday, 30'th Jul 2025
TORONTO, July 30, 2025 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT: 31R), a specialty life sciences company dedicated to deve
Revive Therapeutics Clarifies Completion of Key Nerve Agent Countermeasure Study
05:10pm, Tuesday, 08'th Jul 2025
TORONTO, July 08, 2025 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialized life sciences company dedicated to the
TORONTO, June 26, 2025 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the rese
Revive Therapeutics Advances with Next-Generation Bucillamine Development
06:55am, Wednesday, 04'th Jun 2025
TORONTO, June 04, 2025 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT: 31R), a specialty life sciences company dedicated to deve
Revive Therapeutics Provides Update on Research Study Evaluating Bucillamine for Nerve Agent Exposure
02:07pm, Monday, 12'th May 2025
TORONTO, May 12, 2025 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the resea
Revive Therapeutics Announces Proposed Shares for Debt Transaction
04:30pm, Monday, 21'st Apr 2025
TORONTO, April 21, 2025 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the res
Revive Therapeutics to Investigate Bucillamine's Potential in Cancer Treatment
07:00am, Thursday, 10'th Apr 2025
TORONTO, April 10, 2025 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the res
Revive Therapeutics Announces Acquisition of Molecular Hydrogen Program
07:30am, Tuesday, 01'st Apr 2025
TORONTO, April 01, 2025 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the res
